Impact of


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
11 2023
Historique:
received: 23 05 2023
revised: 01 08 2023
medline: 6 11 2023
pubmed: 8 9 2023
entrez: 7 9 2023
Statut: ppublish

Résumé

Since the development of fibroblast activation protein-targeted radiopharmaceuticals,

Identifiants

pubmed: 37678928
pii: jnumed.123.266046
doi: 10.2967/jnumed.123.266046
pmc: PMC10626373
doi:

Substances chimiques

Gallium Radioisotopes 0
Fluorodeoxyglucose F18 0Z5B2CJX4D
Quinolines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1712-1720

Informations de copyright

© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Références

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):783-791
pubmed: 30353883
J Nucl Med. 2021 Feb;62(2):160-167
pubmed: 33127618
Radiother Oncol. 2021 May;158:55-61
pubmed: 33621587
J Nucl Med. 2018 Sep;59(9):1415-1422
pubmed: 29626119
J Nucl Med. 2018 Sep;59(9):1423-1429
pubmed: 29626120
Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1820-1832
pubmed: 32222810
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1593-1603
pubmed: 33097975
J Nucl Med. 2022 Jan;63(1):127-133
pubmed: 34272325
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4377-4385
pubmed: 34137945
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):196-203
pubmed: 32468254
J Nucl Med. 2020 Sep;61(9):1331-1336
pubmed: 32060216
Arch Bronconeumol. 2014 Mar;50(3):99-104
pubmed: 24360985
Lancet Oncol. 2020 Apr;21(4):581-592
pubmed: 32171429
Cancers (Basel). 2021 Feb 14;13(4):
pubmed: 33672893
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2569-2580
pubmed: 31388723
J Nucl Med. 2021 Feb;62(2):201-207
pubmed: 32591493
Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2960-2971
pubmed: 35462566
J Nucl Med. 2019 Jul;60(7):963-970
pubmed: 30552203
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):11-19
pubmed: 29905907
J Nucl Med. 2021 Jun 1;62(6):779-786
pubmed: 33097632
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4089-4100
pubmed: 34050777
J Nucl Med. 2018 Jul 5;60(2):234-240
pubmed: 29976697
Diagnostics (Basel). 2020 Nov 14;10(11):
pubmed: 33202682
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):988-94
pubmed: 15989999
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):759-767
pubmed: 31377821
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2836-2845
pubmed: 32447444
Nucl Med Commun. 2023 Mar 1;44(3):194-203
pubmed: 36472415
Health Technol Assess. 2018 Feb;22(7):1-114
pubmed: 29402376
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):435-48
pubmed: 16198064
EJNMMI Radiopharm Chem. 2021 Aug 21;6(1):28
pubmed: 34420105
Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3898-3909
pubmed: 35578038
Radiother Oncol. 2021 Jul;160:192-201
pubmed: 33940087
J Nucl Med. 2020 Aug;61(8):1153-1160
pubmed: 31924715
Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):593-7
pubmed: 10348289
Neuroimaging Clin N Am. 2022 May;32(2):287-298
pubmed: 35526957

Auteurs

Stefan A Koerber (SA)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany.
Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany.
Department of Radiation Oncology, Barmherzige Brueder Hospital Regensburg, Regensburg, Germany.

Manuel Röhrich (M)

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany; manuel.roehrich@med.uni-heidelberg.de.
Department of Nuclear Medicine, Mainz University Hospital, Mainz, Germany.

Leon Walkenbach (L)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Jakob Liermann (J)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany.

Peter L Choyke (PL)

Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Christoph Fink (C)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany.

Cathrin Schroeter (C)

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.

Anna-Maria Spektor (AM)

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.

Klaus Herfarth (K)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany.
Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany.

Thomas Walle (T)

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Virotherapy, German Cancer Research Center, Heidelberg, Germany.
German Cancer Consortium, Heidelberg, Germany.

Jeremie Calais (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California.

Hans-Ulrich Kauczor (HU)

Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany.

Dirk Jaeger (D)

Department of Nuclear Medicine, Mainz University Hospital, Mainz, Germany.

Juergen Debus (J)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany.
Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany.
German Cancer Consortium, Heidelberg, Germany.

Uwe Haberkorn (U)

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany.

Frederik L Giesel (FL)

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Department of Nuclear Medicine, Medical Faculty, Heinrich-Heine University, University Hospital Düsseldorf, Düsseldorf, Germany; and.
Institute for Radiation Sciences, Osaka University, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH